[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR106301A1 - Composiciones de pirrolpirimidina como inhibidores de quinasas - Google Patents

Composiciones de pirrolpirimidina como inhibidores de quinasas

Info

Publication number
AR106301A1
AR106301A1 ARP160103082A ARP160103082A AR106301A1 AR 106301 A1 AR106301 A1 AR 106301A1 AR P160103082 A ARP160103082 A AR P160103082A AR P160103082 A ARP160103082 A AR P160103082A AR 106301 A1 AR106301 A1 AR 106301A1
Authority
AR
Argentina
Prior art keywords
alkyl
hydrogen
substituted
halo
hydroxyl
Prior art date
Application number
ARP160103082A
Other languages
English (en)
Inventor
Wang Xiaobo
Xu Wanhong
Xu Xiao
Wu Jian
Mo Xiaopeng
Weng Bojie
Bao Yimei
Dai Kongen
Hua Yuning
Chen Yile
Liu Jia
Mao Long
Original Assignee
Acea Biosciences Inc
Acea Bio Hangzhou Co Ltd
Acea Pharmaceutical Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acea Biosciences Inc, Acea Bio Hangzhou Co Ltd, Acea Pharmaceutical Res Co Ltd filed Critical Acea Biosciences Inc
Publication of AR106301A1 publication Critical patent/AR106301A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Reivindicación 1: Una composición farmacéutica caracterizada porque comprende: (a) un compuesto de la fórmula (1), en donde X¹ es O, NH, o S; R¹ y R² son cada uno, independientemente, hidrógeno, halo, C₁₋₆ alquilo, o C₁₋₆ haloalquilo; R³ es halo, hidroxilo, C₁₋₆ alquilo, C₁₋₆ alcoxi, ciano, o nitro; n es 0, 1, 2, 3 ó 4; R⁴ es hidrógeno, C₁₋₆ alquilo, C₃₋₇ cicloalquilo, o -NR²²R²³; en donde el alquilo y el cicloalquilo no están sustituidos o están sustituidos con hidroxilo o amino; y R²² y R²³ son cada uno, independientemente, hidrógeno o C₁₋₆ alquilo; o R²² y R²³ tomados junto con el nitrógeno al que están unidos, forman un anillo heterocicloalquilo de entre 3 y 10 miembros; R⁵ es hidrógeno o C₁₋₄ alquilo; R⁶ y R⁷ son cada uno, independientemente, hidrógeno, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₂₋₆ alcoxi, C₁₋₆ haloalcoxi, hidroxilo, ciano, o nitro; R⁸ es hidrógeno, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ alcoxi, C₁₋₆ haloalcoxi, hidroxilo, ciano, o nitro; R¹¹ y R¹² son cada uno, independientemente, hidrógeno o C₁₋₆ alquilo; Q es CR⁹ o N; donde R⁹ es hidrógeno, halo, C₁₋₆ alquilo, C₁₋₆ haloalquilo, C₁₋₆ alcoxi, C₁₋₆ haloalcoxi, hidroxilo, ciano, o nitro; -NR¹⁸R¹⁹ es: (a) un compuesto de fórmula (2) ó (3); donde R¹⁰ se selecciona entre hidrógeno y C₁₋₆ alquilo; R¹⁵ es metilo no sustituido, o es C₂₋₄ alquilo no sustituido o sustituido con hidroxi, metoxi, o halo; y m es 1 ó 2; o (b) R¹⁹ y R⁹ se toman junto con los átomos a los que están unidos para formar un anillo heteroarilo de 5 ó 6 miembros, opcionalmente sustituido con C₁₋₆ alquilo, en donde el alquilo no está sustituido o está sustituido con amino, hidroxilo, halo, o un heterocicloalquilo conectado al N; y R¹⁸ es hidrógeno o C₁₋₆ alquilo, donde el alquilo no está sustituido o está sustituido con amino, o R¹⁸ está ausente para satisfacer la valencia del anillo heteroarilo; o Compuesto de fórmula (4), o una sal farmacéuticamente aceptable del compuesto de la fórmula (1) o Compuesto de fórmula (4); y (b) un agente de adsorción que reduce o suprime la formación de un dímero del compuesto, o una sal farmacéuticamente aceptable del mismo.
ARP160103082A 2015-10-09 2016-10-07 Composiciones de pirrolpirimidina como inhibidores de quinasas AR106301A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2015091536 2015-10-09

Publications (1)

Publication Number Publication Date
AR106301A1 true AR106301A1 (es) 2018-01-03

Family

ID=58487279

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103082A AR106301A1 (es) 2015-10-09 2016-10-07 Composiciones de pirrolpirimidina como inhibidores de quinasas

Country Status (14)

Country Link
US (1) US10533011B2 (es)
EP (1) EP3359159B1 (es)
JP (1) JP6889494B2 (es)
KR (1) KR20180067584A (es)
CN (1) CN107949388B (es)
AR (1) AR106301A1 (es)
AU (1) AU2016334141B2 (es)
BR (1) BR112018006939A2 (es)
CA (1) CA3001744A1 (es)
HK (1) HK1253537A1 (es)
MX (1) MX2018004332A (es)
RU (1) RU2018115334A (es)
TW (1) TW201722431A (es)
WO (1) WO2017059702A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9034885B2 (en) 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
EP2802568A1 (en) * 2012-01-13 2014-11-19 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents.
WO2015006754A2 (en) 2013-07-11 2015-01-15 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
EP3359159B1 (en) 2015-10-09 2023-06-07 ACEA Therapeutics, Inc. Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
CA3059072A1 (en) * 2017-04-07 2018-10-11 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same
US20210308140A1 (en) 2018-07-25 2021-10-07 Novartis Ag Nlrp3 inflammasome inhibitors
CN112752750A (zh) * 2018-08-09 2021-05-04 艾森医药公司 (s)-n-(3-((2-((4-((1-乙酰基吡咯烷-3-基)(甲基)氨基)苯基)氨基)-5-甲氧基嘧啶-4-基)氧基)苯基)丙烯酰胺的制备方法及其制剂
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CN110407840A (zh) * 2019-08-15 2019-11-05 重庆化工职业学院 一种艾维替尼的制备方法
AR123241A1 (es) 2020-08-14 2022-11-09 Novartis Ag Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos
CN111848631B (zh) * 2020-08-28 2022-04-19 四川大学华西医院 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途
CN114573591B (zh) * 2022-04-16 2023-04-25 成都施贝康生物医药科技有限公司 一种取代的吡咯并嘧啶化合物及其应用
US20240067627A1 (en) 2022-08-03 2024-02-29 Novartis Ag Nlrp3 inflammasome inhibitors
WO2024092047A1 (en) 2022-10-26 2024-05-02 Sorrento Therapeutics, Inc. Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3974277A (en) 1974-09-06 1976-08-10 Diamond Shamrock Corporation 2-[2-(5-Nitro-2-furyl)vinyl]-4-(anilino)quinazolines as growth promotants and feed efficiency enhancing agents
EP1230225A2 (en) 1999-11-01 2002-08-14 Eli Lilly And Company Pharmaceutically active 4-substituted pyrimidine derivatives
DE60237145D1 (de) 2001-02-21 2010-09-09 Mitsubishi Tanabe Pharma Corp Chinazolinderivate
US6881737B2 (en) 2001-04-11 2005-04-19 Amgen Inc. Substituted triazinyl acrylamide derivatives and methods of use
WO2003026665A1 (en) 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4-(5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
US7468255B2 (en) 2002-12-20 2008-12-23 Acea Biosciences Method for assaying for natural killer, cytotoxic T-lymphocyte and neutrophil-mediated killing of target cells using real-time microelectronic cell sensing technology
US7732127B2 (en) 2002-12-20 2010-06-08 Acea Biosciences, Inc. Dynamic monitoring of cell adhesion and spreading using the RT-CES system
US7470533B2 (en) 2002-12-20 2008-12-30 Acea Biosciences Impedance based devices and methods for use in assays
US7560269B2 (en) 2002-12-20 2009-07-14 Acea Biosciences, Inc. Real time electronic cell sensing system and applications for cytotoxicity profiling and compound assays
ATE448482T1 (de) 2002-07-20 2009-11-15 Acea Biosciences Inc Vorrichtungen auf impedanzbasis sowie verfahren zur verwendung in assays
JP2006503826A (ja) 2002-09-06 2006-02-02 スミスクライン・ビーチャム・コーポレイション ピロロ［２，３−ｄ］ピリミジン−４−イルおよびプリン−６−イル尿素化合物
TW200416034A (en) 2002-11-15 2004-09-01 Mitsubishi Pharma Corp Medicinal composition
EP1692258A4 (en) 2003-11-12 2007-03-21 Xiao Xu REAL-TIME ELECTRONIC CELL DETECTION SYSTEMS FOR CELL-BASED TESTS
PL1696920T3 (pl) 2003-12-19 2015-03-31 Plexxikon Inc Związki i sposoby opracowywania modulatorów Ret
WO2005065156A2 (en) 2003-12-23 2005-07-21 First Data Corporation Global positioning system
EP1720877A4 (en) 2004-03-02 2009-11-04 Neurogen Corp ANALOGUES OF PURINS ARYL SUBSTITUTION
CA2570817A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
RS52383B (en) 2005-09-21 2012-12-31 4Sc Ag NEW SULFONYLPYROLS AS HDAC INHIBITORS
BRPI0617241A2 (pt) 2005-10-13 2016-11-08 Glaxo Group Ltd composto ou um sal ou solvato do mesmo, composição farmacêutica, método para tratar uma doença ou condição mediada por atividade syk inadequada em um mamífero, e, uso de um composto ou um sal ou solvato farmaceuticamente aceitável do mesmo
KR100832594B1 (ko) 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
GB0526246D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
EP2010183A4 (en) 2006-03-03 2010-08-25 Aveo Pharmaceuticals Inc PROCESS FOR SYNTHESIS OF 7-ALKINYL-4-AMINOCHINAZOLINES AND A RELATED INTERMEDIATE COMPOUND
BRPI0709699A2 (pt) 2006-03-29 2011-07-26 Foldrx Pharmaceuticals Inc inibiÇço da toxidez da alfa-sinucleina
US8314234B2 (en) 2006-09-25 2012-11-20 Janssen Pharmaceutica N.V. Bicyclic pyrimidine kinase inhibitors
DK2091918T3 (en) 2006-12-08 2014-12-01 Irm Llc Compounds and Compositions as Protein Kinase Inhibitors
CN101622001A (zh) 2007-01-26 2010-01-06 Irm责任有限公司 作为激酶抑制剂用于治疗疟原虫相关疾病的嘌呤化合物和组合物
CA2702647C (en) 2007-01-31 2016-03-22 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
WO2008145143A1 (en) 2007-05-30 2008-12-04 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
TWI377944B (en) 2007-06-05 2012-12-01 Hanmi Holdings Co Ltd Novel amide derivative for inhibiting the growth of cancer cells
WO2009017838A2 (en) 2007-08-01 2009-02-05 Exelixis, Inc. Combinations of jak-2 inhibitors and other agents
JP5298128B2 (ja) 2007-08-08 2013-09-25 グラクソスミスクライン エルエルシー 癌の治療用のＩＧＦ−１Ｒ阻害剤としての２−［（２−｛フェニルアミノ｝−１Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）アミノ］ベンズアミド誘導体
WO2009032703A1 (en) 2007-08-28 2009-03-12 Irm Llc 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors
EP2214486A4 (en) 2007-10-19 2011-03-09 Avila Therapeutics Inc HETEROARYL COMPOUNDS AND ITS USES
US7989465B2 (en) 2007-10-19 2011-08-02 Avila Therapeutics, Inc. 4,6-disubstituted pyrimidines useful as kinase inhibitors
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CN102105150B (zh) 2008-05-21 2014-03-12 阿里亚德医药股份有限公司 用作激酶抑制剂的磷衍生物
JP2011526299A (ja) 2008-06-27 2011-10-06 アビラ セラピューティクス， インコーポレイテッド ヘテロアリール化合物およびそれらの使用
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2010045451A1 (en) 2008-10-16 2010-04-22 Glaxosmithkline Llc Pyrrolopyrimidine compounds
AU2010210986A1 (en) 2009-02-09 2011-08-25 Supergen, Inc. Pyrrolopyrimidinyl Axl kinase inhibitors
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
US20130137709A1 (en) 2010-05-05 2013-05-30 Nathanael S. Gray Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith
SG186378A1 (en) 2010-06-23 2013-01-30 Hanmi Science Co Ltd Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity
WO2012061303A1 (en) 2010-11-01 2012-05-10 Avila Therapeutics, Inc. Heteroaryl compounds and uses thereof
KR101954593B1 (ko) 2010-11-01 2019-03-06 셀젠 카르 엘엘씨 헤테로사이클릭 화합물 및 이의 용도
ES2665013T3 (es) 2010-11-10 2018-04-24 Celgene Car Llc Inhibidores de EGFR selectivos de mutante y usos de los mismos
CN102583089B (zh) 2011-01-11 2015-11-25 山东新北洋信息技术股份有限公司 薄片类介质处理装置
KR20130141673A (ko) 2011-03-07 2013-12-26 폰다지오네 텔레톤 Tfeb 인산화 저해제 및 그의 용도
US8703767B2 (en) 2011-04-01 2014-04-22 University Of Utah Research Foundation Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitors
CN103501612B (zh) 2011-05-04 2017-03-29 阿里亚德医药股份有限公司 抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
US9586965B2 (en) * 2012-01-13 2017-03-07 Acea Biosciences Inc. Pyrrolo[2,3-d]pyrimidine compounds as inhibitors of protein kinases
US9464089B2 (en) 2012-01-13 2016-10-11 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
EP2802568A1 (en) 2012-01-13 2014-11-19 Acea Biosciences, Inc. Heterocyclic compounds and uses as anticancer agents.
US9034885B2 (en) * 2012-01-13 2015-05-19 Acea Biosciences Inc. EGFR modulators and uses thereof
UA115983C2 (uk) * 2012-04-24 2018-01-25 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори днк-пк
DK2880035T3 (en) 2012-08-06 2017-03-06 Acea Biosciences Inc Hitherto UNKNOWN PYRROLOPYRIMIDINE COMPOUNDS AS PROTEIN CHINAS INHIBITORS
WO2015006754A2 (en) 2013-07-11 2015-01-15 Acea Biosciences Inc. Heterocyclic compounds and uses thereof
CN104306348B (zh) 2014-09-30 2017-05-31 地奥集团成都药业股份有限公司 一种辛伐他汀片及其制备方法
CN105185339B (zh) 2015-10-08 2017-12-29 京东方科技集团股份有限公司 移位寄存器单元、栅线驱动装置以及驱动方法
EP3359159B1 (en) 2015-10-09 2023-06-07 ACEA Therapeutics, Inc. Pharmaceutical compositions of a pyrrolopyrimidine kinase inhibitor, and methods of making same
WO2017085056A1 (en) 2015-11-16 2017-05-26 Topadur Pharma Ag 2-phenyl-3,4-dihydropyrrolo[2,1 -f] [1,2,4]triazinone derivatives as phosphodiesterase inhibitors and uses thereof
CA3059072A1 (en) 2017-04-07 2018-10-11 ACEA Therapeutics, Inc. Pharmaceutical salts, physical forms, and compositions of pyrrolopyrimidine kinase inhibitors, and methods of making same

Also Published As

Publication number Publication date
HK1253537A1 (zh) 2019-06-21
AU2016334141B2 (en) 2019-12-19
EP3359159B1 (en) 2023-06-07
JP6889494B2 (ja) 2021-06-18
JP2018530610A (ja) 2018-10-18
EP3359159A4 (en) 2019-06-05
RU2018115334A (ru) 2019-11-11
US10533011B2 (en) 2020-01-14
WO2017059702A1 (en) 2017-04-13
US20180312510A1 (en) 2018-11-01
EP3359159A1 (en) 2018-08-15
MX2018004332A (es) 2019-01-10
CN107949388B (zh) 2021-10-26
KR20180067584A (ko) 2018-06-20
CN107949388A (zh) 2018-04-20
BR112018006939A2 (pt) 2018-10-16
AU2016334141A1 (en) 2018-04-26
CA3001744A1 (en) 2017-04-13
RU2018115334A3 (es) 2019-11-29
TW201722431A (zh) 2017-07-01

Similar Documents

Publication Publication Date Title
AR106301A1 (es) Composiciones de pirrolpirimidina como inhibidores de quinasas
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR110922A1 (es) Compuestos inhibidores del vih
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR094557A1 (es) Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con deficiencia de smn
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR088449A1 (es) Benzilindazoles sustituidos
AR092742A1 (es) Piridinonas antifibroticas
AR098872A1 (es) Moduladores de tetrahidropiridopirazinas de gpr6
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR097866A1 (es) Derivados de 4-azaindol
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR088014A1 (es) Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa
AR091185A1 (es) Derivados de 1,2,4-triazol
AR098492A1 (es) Derivados de purina
AR093758A1 (es) Inhibidores de aril lactama quinasa
AR114369A1 (es) Dinucleótidos cíclicos como agentes antineoplásicos
AR102258A1 (es) Compuestos de quinolina y quinazolina
AR100940A1 (es) Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados
AR107054A1 (es) DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt
AR097403A1 (es) Derivados de benzamida como antagonistas de lpar1 y/o lpar5 y un proceso para su preparación
AR100706A1 (es) Derivados de naftiridinadiona
AR096423A1 (es) Compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona

Legal Events

Date Code Title Description
FB Suspension of granting procedure